Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | GAK | O14976 | 1/20 | 0.47 |
| ▸ | FBP1 | P09467 | 1/20 | 0.45 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.44 |
| ▸ | EGFR | P00533 | 2/20 | 0.44 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.44 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.44 |
| ▸ | SYK | P43405 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.41 |
| ▸ | APP | P05067 | 2/20 | 0.40 |
| ▸ | DHFR | P00374 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2621790 | 0.87 | PDGFRB (0.50) | HPGDSMN1; SMN2GAKFBP1EGFR | |
| SCHEMBL29892755 | 0.84 | GAK (0.61) | GAKFBP1ALKEGFRERBB2 | |
| SCHEMBL3304514 | 0.84 | GAK (0.61) | GAKFBP1ALKEGFRERBB2 | |
| SCHEMBL9452129 | 0.82 | EGFR (0.50) | SMN1; SMN2GAKALKEGFRPDGFRB | |
| SCHEMBL29214659 | 0.81 | ALK (0.42) | SMN1; SMN2GAKALKEGFRSYK | |
| SCHEMBL10377143 | 0.80 | POLB (0.63) | HPGDSMN1; SMN2GAKPOLBTHRB | |
| SCHEMBL28175249 | 0.80 | SYK (0.43) | HPGDSMN1; SMN2SYKPOLBTHRB | |
| SCHEMBL29214649 | 0.79 | GAK (0.41) | SMN1; SMN2GAKFBP1ALKEGFR | |
| SCHEMBL27920759 | 0.79 | LMNA (0.47) | HPGDSMN1; SMN2GAKALKEGFR | |
| SCHEMBL13443841 | 0.79 | HTR1A (0.57) | GAKSYKAPP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250145599-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | MRJA THERAPEUTICS, INC. | 2025-05-08 | — | — | US | disclosed |
| CN-118974019-A | Certain chemical entities, compositions and methods | 瑞图恩制药公司 | 2024-11-15 | — | — | CN | disclosed |
| WO-2023150663-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | RETUNE PHARMA INC. (US) | 2023-08-10 | — | — | WO | disclosed |
| EP-3247705-B1 | QUINAZOLINE AND QUINOLINE COMPOUNDS AND USES THEREOF AS NAMPT INHIBITORS | MILLENNIUM PHARM INC (US) | 2019-11-20 | — | — | EP | disclosed |
| EP-3247705-B1 | QUINAZOLINE AND QUINOLINE COMPOUNDS AND USES THEREOF AS NAMPT INHIBITORS | MILLENNIUM PHARM INC (US) | 2019-11-20 | — | — | EP | disclosed |
| US-10323018-B2 | Quinazoline and quinoline compounds and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2019-06-18 | — | — | US | disclosed |
| US-20180009784-A1 | QUINAZOLINE AND QUINOLINE COMPOUNDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. | 2018-01-11 | — | — | US | disclosed |
| US-20180009784-A1 | QUINAZOLINE AND QUINOLINE COMPOUNDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. | 2018-01-11 | — | — | US | disclosed |
| EP-3247705-A1 | QUINAZOLINE AND QUINOLINE COMPOUNDS AND USES THEREOF | Millennium Pharmaceuticals, Inc. (US) | 2017-11-29 | — | — | EP | disclosed |
| WO-2016118565-A1 | QUINAZOLINE AND QUINOLINE COMPOUNDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2016-07-28 | — | — | WO | disclosed |
| WO-2016118565-A1 | QUINAZOLINE AND QUINOLINE COMPOUNDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2016-07-28 | — | — | WO | disclosed |
| EP-2637660-A1 | FATTY ACID SYNTHASE INHIBITORS | Glaxosmithkline Intellectual Property (No. 2) Limited (GB) | 2013-09-18 | — | — | EP | disclosed |
| US-20130237535-A1 | FATTY ACID SYNTHASE INHIBITORS | GLAXOSMITHKLINE LLC | 2013-09-12 | — | — | US | disclosed |
| WO-2012064642-A1 | FATTY ACID SYNTHASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2012-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10323018-B2 | Quinazoline and quinoline compounds and uses thereof | NAMPT, NQO2, NNMT | HPGD 713/4885SMN1; SMN2 3803/4885GAK 2865/4885 |
| US-20130237535-A1 | FATTY ACID SYNTHASE INHIBITORS | FASN, FADS1, FADS2 | HPGD 487/4885SMN1; SMN2 4521/4885GAK 1515/4885 |
| US-20250145599-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | IGF1R, IGFBP1, IGFBP2 | HPGD 1604/4885SMN1; SMN2 1317/4885GAK 1727/4885 |
| US-20180009784-A1 | QUINAZOLINE AND QUINOLINE COMPOUNDS AND USES THEREOF | NAMPT, NQO2, NNMT | HPGD 713/4885SMN1; SMN2 3803/4885GAK 2865/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.